Optimized vaccine development and manufacturing: A technology overview

BioPharm International

Volumn 21, Issue 1 SUPPL., 2008, Pages 38-42

  Fetzer, Silke ^a  

^a GE HEALTHCARE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG DESIGN; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; ENZYME LINKED IMMUNOSORBENT ASSAY; REVIEW; SURFACE PLASMON RESONANCE;

EID: 39149109963     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Heuer A, Editor's Note. The Bridge. 2006 Fall;36(3):3.
2. Wood JM, Mumford J, Schild GC, Wbster RG, Nicholson KG. Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals. Dev Biol Stand. 1985;64:169-77.
3. Pol E, et al. Biosensor-based characterization of serum antibodies during development of an anti-IgE immunotherapeutic against allergy and asthma. J Mol Recognit. 2007 Jan-Feb;20(1):22-31.
4. Biacore AB and Boehinger Ingelheim Pharma, Germany. Fast In-Process and Quality Control. Application Note Biacore, GE Healthcare AB.
5. Development of immunotherapeutics and immunization regimes using Biacore T100, Application Note 79, GE Healthcare AB.
6. Metz B, Jiskoot W, Hennink WE, Crommelin DJ, Kersten, Vaccine. 2003 Dec 12;22(2):156-67.
7. US Food and Drug Administration. Guidance for Industry. Characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases. Rockville, MD; 2006.
8. European Pharmacopoeia 5th Edition 5.06.
9. For requirements for seasonal influenza, see Michael Osterholm, Preparing for the Next Pandemic. New England J of Med. 2005 vol 352:18:1839-1843; for requirements for pandemic influenza, see Department of Health and Human Services, Vaccine Production in Cells. Available from www.pandemicflu.gov/ vaccine/vproductioncells.html.
10. Ozturk SS. Engineering challenges in high density cell culture systems. Cytotechnology. 1996(22):3-16.
11. Malhaise E. Cell-culture based vaccine production. NAE/IOM topical conference: Technological Options. 2006 Apr 10-11;Cleveland, OH.
12. Aycardi E. Conference on Producing Vaccines for Developing Nations BioPharm. 2002(5):8-10.
13. Kistner O, et al. Development of safe and immunogenic mammalian cell (Vero) derived inactivated H5N1 whole virus candidate vaccine using the H5N1 wild type human isolate A/VietNam/1203/2004. Influenza Vaccines for the World conference. 2006; Vienna, Austria.
14. Coffman J, et al. High-Throughput Screening of Resins and Excipients for Downstream Process Development. IBC Bioprocess International Conference. 2004 Oct; Boston.
15. Kelley B, Switzer M, Booth J, Coffman J. Application of High Throughput Screening to a Mab Purification Platform. IBC Bioprocess International Conference. 2005 Sept; Boston.
16. Bezy P. Efficient Pilot Plant Utilization. Presented at IBC BioProcess International Conference. 2005 Apr; Berlin.
17. Kang Y, Cuttler MW, Quattara AA, Syvertsen KE. Purification processes for isolating purified vesicular stomatits virus from cell culture. United States patent publication no. US/2007 0249019 A1, published Oct 25, 2007.
18. Tal J. Adeno associated Virus-based Vectors in Gene Therapy. J Biomedical Sci. 2000(7):279-291.
19. Kaludov N, et al. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Human Gene Therapy. 2002;13(10):1235-43.
20. Kalbfuss B. et al. Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Biotechnol Bioeng. 2007;96(5):932-944.
21. Novais JL, Titchener-Hooker NJ, Hoare M. Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. Biotechnol and Bioengi. 2001;75(2):143-153.
22. Gen Engi news. 2004;24(8).
23. 3rd Annual Report and Survey of Biopharmaceutical Manufacturing, Capacity and Production.
24. Sinclair A, Monge M. Biomanufacturing for the 21st Century: Designing a concept facility based on single-use systems. BioProcess Int. 2004 Oct supp:26-31.